BioWorld® - Medical Device Daily

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
Research laboratories in Osaka and Tsukuba
Farm and herbal garden in Fukuchiyama and Kyoto
STOCK-FINANCIAL HISTORY: Listed on the Tokyo, Osaka, Nagoya, Fukuoka and Sapporo stock
exchanges
Net sales ¥1,212b (YE 05) compared to ¥1,122b (YE 04)
Net income ¥313.249b (YE 05) compared to ¥277.438b (YE 04)
Earnings per share ¥353.47/share (YE 05) compared to ¥313.01/share (YE
04)
Total assets ¥3,042b (YE 05) compared to ¥2,545b (YE 04)
SUBSIDIARIES/DIVISIONS: Takeda America Holdings Inc.--New York, N.Y.
Takeda Research Investment Inc.--Palo Alto, Calif.
Takeda San Diego Inc.--San Diego, Calif.
Takeda Pharmaceuticals North America Inc.--Lincolnshire, Ill.
Takeda Global Research and Development Center Inc.--Lincolnshire, Ill.
TAP Pharmaceutical Products Inc.--Lake Forest, Ill.
Takeda Global Research & Development Centre (Europe) Ltd.--London
Laboratoires Takeda--France
Takeda UK Ltd.
Takeda Italia Farmaceutici SpA--Rome, Italy
Takeda Pharma GmbH--Germany
Takeda Pharma Ges. mbH--Vienna, Austria
Takeda Pharma AG--Lachen, Switzerland
Takeda Ireland Ltd.--Wicklow, Ireland
Takeda Pharma Ireland Ltd.--Dublin, Ireland
Tianjin Takeda Pharmaceuticals Co. Ltd.--China
Takeda Chemical Industries (Taiwan) Ltd.--Taipei, Taiwan
Boie-Takeda Chemicals Inc.--The Phillipines
Takeda (Thailand) Ltd.--Bangkok, Thailand
P.T. Takeda Indonesia--Indonesia
INVESTMENTS: Wyeth-Lederle (Japan) Ltd.--30%
TAP Pharmaceutical Products Inc.--50% (joint venture with Abbott
Laboratories)
Laboratoires Takeda--100%
Takeda Italia Farmaceutici SpA--76.92% (with Finfarma SpA)
Tianjin Takeda Pharmaceuticals Co. Ltd.--75% (with Tainjin Lisheng
Pharmaceutical Factory)
AGREEMENTS: Name Products Content of Agreement Date
3M
topical treatment for exclusive co- 2/05
Pharmaceuticals cervical high-risk HPV development and
infection and cervical joint marketing
dysplasia
agreement
Abbott
drug for prostate cancer joint venture called 8/77
Laboratories and ulcer
TAP Holdings to
market drug
developed by
Takeda
Affymax Inc. Affymax's Hematide in development and 2/06
Japan
commercialization
agreement
Affymax Inc. Affymax's Hematide in development and 6/06
the U.S.
commercialization
agreement
Ajinomoto risedronate for
codevelopment 1992
osteoporosis
agreement for
Japan and South
Korea
Alizyme plc development,
manufacturing and
marketing of ATL-962 in
Japan
licensing agreement 1/04
Copyright ©2006 AHC Media ® 366